研究者業績

立枩 良崇

タテマツ ヨシタカ  (yoshitaka tatematsu)

基本情報

所属
藤田医科大学 医学部 内科学 助教

J-GLOBAL ID
202301010923401427
researchmap会員ID
R000054619

論文

 7
  • Yoshitaka Tatematsu, Takahiro Imaizumi, Nobuaki Michihata, Noritoshi Kato, Ryosuke Kumazawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Shoichi Maruyama
    Scientific Reports 14(1) 2024年8月6日  査読有り筆頭著者
  • Kosuke Osawa, Shuto Yamamoto, Yukiko Yamano, Ayako Kita, Kota Okamoto, Noritoshi Kato, Yoshitaka Tatematsu, Fumiyoshi Kojima, Masaki Ohya, Shigeo Hara, Shin-ichi Murata, Norimitsu Inoue, Shoichi Maruyama, Shin-ichi Araki
    Internal Medicine 63(12) 1777-1782 2024年6月15日  査読有り
  • Daijo Inaguma, Yoshitaka Tatematsu, Naoki Okamoto, Soshiro Ogata, Hideki Kawai, Eiichi Watanabe, Yukio Yuzawa, Midori Hasegawa, Naotake Tsuboi
    BMJ Open 14(1) e076962-e076962 2024年1月24日  査読有り
    Introduction Coronary artery and heart valve calcification is a risk factor for cardiovascular death in haemodialysis patients, so calcification prevention should be started as early as possible. Treatment with concomitant calcimimetics and low-dose vitamin D receptor activators (VDRAs) is available, but not enough evidence has been obtained on the efficacy of this regimen, particularly in patients with short dialysis duration. Therefore, this study will evaluate the efficacy and safety of early intervention with upacicalcet, a calcimimetic used to prevent coronary artery calcification in this patient population. Methods and analysis This multicentre, open-label, randomised, parallel-group controlled study will compare an early intervention group, which received upacicalcet and a low-dose VDRA, with a conventional therapy group, which received a VDRA. The primary endpoint is a change in log coronary artery calcium volume score from baseline to 52 weeks. The main inclusion criteria are as follows: (1) age 18 years or older; (2) dialysis is planned or dialysis duration is less than 60 months; (3) intact parathyroid hormone (PTH) >240 pg/mL or whole PTH level>140 pg/mL; (4) serum-corrected calcium≥8.4 mg/dL and (5) Agatston score >30. The main exclusion criteria are as follows: (1) history of parathyroid intervention or fracture in the past 12 weeks; (2) history of myocardial infarction, stroke or leg amputation in the past 12 weeks; (3) history of coronary angioplasty and (4) heart failure of New York Heart Association class III or worse. Ethics and dissemination The study will comply with the Declaration of Helsinki and the Japanese Clinical Trials Act. The study protocol has been approved by the Fujita Health University Certified Review Board (file no. CR22-052). Written informed consent will be obtained from all participants. Study results will be presented in academic meetings and peer-reviewed academic journals. Trial registration number jRCTs041220126.
  • Sawako Kato, Yachiyo Kuwatsuka, Masahiko Ando, Yoshitaka Tatematsu, Nobuhiro Nishibori, Shoichi Maruyama
    BMC Nephrology 24(1) 2023年8月3日  査読有り
    Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are considered to have the potential to maintain renal function by correcting glomerular hypertension in patients with diabetic kidney disease (DKD). The aim of this study is to demonstrate the renoprotective effect of SGLT2i by measuring renal hemodynamics, including glomerular filtration fraction (FF), in type 2 diabetic patients with moderate renal dysfunction. Methods Renoprotective effect of canagliflozin derived from test of renal hemodynamics in diabetic kidney disease (FAGOTTO) study is a 12-week multicenter, open-label, randomized (1:1), parallel-group trial of type 2 diabetic patients with diabetic kidney disease (30 ≤ estimated glomerular filtration rate [eGFR] ≤ 60 mL/min/1.73 m2). A total of 110 patients are to be randomly allocated to receive once-daily canagliflozin 100 mg or control (standard therapy). FF will be calculated by dividing the measured GFR (mGFR) by the effective renal plasma flow (eRPF). mGFR and eRPF will be measured by the clearance of inulin and para-aminohippuric acid (PAH), respectively. The primary endpoint of this trial is the percentage change in FF after 4 weeks of treatment in the canagliflozin and control groups. Discussion The FAGOTTO study will elucidate the mechanism of the renoprotective action of SGLT2i. The background, rationale, and study design of this trial are presented. To date, > 80 patients have been enrolled in this trial. The study will end in 2025. Trial registration jRCT (Japan Registry Of Clinical Trials) jRCTs041200069. Date of registration: November 27, 2020.
  • Yuji Sasakawa, Yoshitaka Tatematsu, Joichiro Kato, Maya Fujii, Naoki Okamoto, Daijo Inaguma
    Clinical and Experimental Nephrology 27(9) 747-756 2023年6月2日  査読有り
  • Yoshihiro Nakamura, Noritoshi Kato, Yoshitaka Tatematsu, Yoshifumi Arai, Nozomi Mori, Katsuaki Shibata, Michiko Yamazaki, Hirotoshi Yasui, Shinji Fujiwara, Taishi Yamakawa, Shoichi Maruyama
    CEN Case Reports 13(1) 37-44 2023年5月22日  査読有り
  • Ryuta Uwatoko, Mayu Shindo, Nobuhiro Hashimoto, Rei Iio, Yoshiyasu Ueda, Yoshitaka Tatematsu, Noritoshi Kato, Shoichi Maruyama, Terumasa Hayashi
    Journal of Nephrology 36(5) 1439-1442 2023年3月6日  査読有り